세포주 개발 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유래별, 세포주 유형별, 용도별, 지역별, 부문별 예측(2025-2033년)

Cell Line Development Market Summary

The global cell line development market size was estimated at USD 5.70 billion in 2024 and is projected to reach USD 13.46 billion by 2033, growing at a CAGR of 10.10% from 2025 to 2033. The growth is fueled by rising demand for biopharmaceuticals, increasing R&D investments, and advancements in cell culture technologies.

Innovations such as automation, single-use systems, and CRISPR-based editing enhance efficiency, driving adoption through the forecast period.

Technological Advancements in Cell Line Development

Rapid advancements in biotechnology are pivotal in driving the cell line development market forward. Innovative tools such as automation, high-throughput screening, and single-use bioprocessing technologies have significantly enhanced cell line generation's speed, efficiency, and cost-effectiveness. Automation and digitalization reduce manual errors, shorten development timelines, and enable large-scale parallel experiments, allowing companies to accelerate product pipelines.

Moreover, cutting-edge genome editing tools like CRISPR/Cas9 are revolutionizing the precision and reliability of cell line engineering. These technologies allow targeted modifications, improved gene expression, and the development of high-yield cell lines with enhanced stability and productivity. Such innovations support the manufacturing of complex biologics and address the growing need for personalized and next-generation therapies. Technological advancements are establishing themselves as a core growth driver by enabling faster turnaround, reduced costs, and greater consistency, ensuring that cell line development remains a critical enabler of progress in the biopharmaceutical industry.

Cell Line Development Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell line development market report on the basis of product & services, source, type of cell lines, application, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents and media
• Equipment
  • Automated Systems
  • Centrifuges
  • Bioreactors
  • Storage equipment
  • Others
• Accessories & consumables
• Services
• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Mammalian cell line
• Non-mammalian cell line
  • Insects
  • Amphibians
• Type of Cell Lines Outlook (Revenue, USD Million, 2021 - 2033)
• Recombinant cell lines
• Hybridomas
• Continuous cell lines
• Primary cell lines
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Bioproduction
• Drug discovery
• Toxicity testing
• Tissue engineering & Regenerative Medicine
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product & Services
  • 1.1.2. Source
  • 1.1.3. Type of Cell Lines
  • 1.1.4. Application
• 1.2. Market Definitions
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Others
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Growing biopharmaceutical production
    • 3.3.1.2. Technological advancements
• 3.4. Market Restraint Analysis
  • 3.4.1.1. Presence of complicated regulatory framework
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Product & Services Business Analysis

• 4.1. Product & Services Segment Dashboard
• 4.2. Global Cell Line Development Market: Product & Services Movement Analysis
• 4.3. Global Cell Line Development Market Size & Trend Analysis, by Product & Services, 2021 to 2033 (USD Million)
• 4.4. Reagents and Media
  • 4.4.1. Reagents and Media Market, 2021 - 2033 (USD Million)
• 4.5. Equipment
  • 4.5.1. Equipment Market, 2021 - 2033 (USD Million)
  • 4.5.2. Automated Systems
    • 4.5.2.1. Automated Systems Market, 2021 - 2033 (USD Million)
  • 4.5.3. Centrifuges
    • 4.5.3.1. Centrifuges Market, 2021 - 2033 (USD Million)
  • 4.5.4. Bioreactors
    • 4.5.4.1. Bioreactors Market, 2021 - 2033 (USD Million)
  • 4.5.5. Storage Equipment
    • 4.5.5.1. Storage Equipment Market, 2021 - 2033 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Others Market, 2021 - 2033 (USD Million)
• 4.6. Accessories and Consumables
  • 4.6.1. Accessories and Consumables Market, 2021 - 2033 (USD Million)
• 4.7. Services
  • 4.7.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Source Business Analysis

• 5.1. Source Segment Dashboard
• 5.2. Global Cell Line Development Market: Source Movement Analysis
• 5.3. Global Cell Line Development Market Size & Trend Analysis, by Source, 2021 to 2033 (USD Million)
• 5.4. Mammalian Cell Line
  • 5.4.1. Mammalian Cell Line Market, 2021 - 2033 (USD Million)
• 5.5. Non-Mammalian Cell Line
  • 5.5.1. Non-Mammalian Cell Line Market, 2021 - 2033 (USD Million)
  • 5.5.2. Insects
    • 5.5.2.1. Insects Market, 2021 - 2033 (USD Million)
  • 5.5.3. Amphibians
    • 5.5.3.1. Amphibians Market, 2021 - 2033 (USD Million)

Chapter 6. Type of Cell Lines Business Analysis

• 6.1. Type of Cell Lines Segment Dashboard
• 6.2. Global Cell Line Development Market: Type of Cell Lines Movement Analysis
• 6.3. Global Cell Line Development Market Size & Trend Analysis, by Type of Cell Lines, 2021 to 2033 (USD Million)
• 6.4. Recombinant Cell Lines
  • 6.4.1. Recombinant Cell Lines Market, 2021 - 2033 (USD Million)
• 6.5. Hybridomas
  • 6.5.1. Hybridomas Market, 2021 - 2033 (USD Million)
• 6.6. Continuous Cell Lines
  • 6.6.1. Continuous Cell Lines Market, 2021 - 2033 (USD Million)
• 6.7. Primary Cell Lines
  • 6.7.1. Primary Cell Lines Market, 2021 - 2033 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Cell Line Development market: Application Movement Analysis
• 7.3. Global Cell Line Development Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 7.4. Bioproduction
  • 7.4.1. Bioproduction Market, 2021 - 2033 (USD Million)
• 7.5. Drug Discovery
  • 7.5.1. Drug Discovery Market, 2021 - 2033 (USD Million)
• 7.6. Toxicity Testing
  • 7.6.1. Toxicity Testing Market, 2021 - 2033 (USD Million)
• 7.7. Tissue Engineering & Regenerative Medicine
  • 7.7.1. Tissue Engineering & Regenerative Medicine Market, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Global Cell Line Development Market Share By Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. North America Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico Cell Line Development Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Germany Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. UK Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway Cell Line Development Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. South Korea Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Australia Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Thailand Cell Line Development Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina Cell Line Development Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE Cell Line Development Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait Cell Line Development Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market/Position Share Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Danaher
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Merck KGaA
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Sartorius AG
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Lonza
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. WuXi PharmaTech
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Advanced Instruments
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Berkeley Lights
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Creative BioLabs
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Corning Inc.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives